RE:RE:RE:RE:RE:New Press Release - Theratechnologies Announces Path to Resume TH1902 Clinical DevelopmentI think I have lower expectations than others about what is achievable in the lab and with a SAC. I think it's most likely they won't come up with anything more than hypotheses about what went wrong. They should be able to rule out certain possibilities but being able to put their finger clearly on what caused the first trial to fail seems unlikely to me. In that scenario the only way to go further is to test the best hypothesis in the clinic by recruiting more patients. I can't see a partner stumping up money to test hypotheses so if they want the program to move forward they'll need to pay to recruit more patients at least in the first instance. As you say that might not be a viable financial option atm if their priority is to get cash positive.
To put it another way. You are trying to jump from a failed path to a successful path. I can't see that leap happening only with data from the lab and input from a SAC, my expectation is it will need more clinical data too. I don't see a partner paying to help make the leap. They'll only come in if the leap is successful so THTX will have to take on the risk of the leap themselves.
We shouldn't rule out that the SAC and the lab work is just due diligence before closing down the program. They've invested a lot in the SORT1 program. tThey have to show they've thoroughly thought through they next decision, that would include the decision to park the program.